Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

116
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
116
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

69
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
69
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

102
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
102
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

131
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
131
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

203
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
203
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

86
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
86

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Non-anesthesiologist-administered propofol sedation for gastrointestinal endoscopy in ASA III patients: Eight-year experience.

Endoscopy international open·2026
Same author

Severe Low Flow Aortic Stenosis With Preserved Ejection Fraction: Latest Diagnostic and Therapeutic Approach.

The American journal of cardiology·2026
Same author

Endoscopic reconstruction of complete post-radiation esophageal and neopharyngeal obliteration.

Endoscopy·2026
Same author

Transcatheter Versus Sutureless Aortic Valve Replacement: A Propensity-Matched Single-Center Cohort Study.

Medicina (Kaunas, Lithuania)·2026
Same author

Unnecessary ERCPs: Is Spontaneous Stone Passage the Sole Determinant?

Medicina (Kaunas, Lithuania)·2026
Same author

MiniMed<sup>TM</sup> 780G Hybrid Closed-Loop Systems Improves Markers of Vascular and Endothelial Function in Patients with Type 1 Diabetes: Association with Continuous Glucose Monitoring Metrics.

Diabetes technology & therapeutics·2026
Same journal

Lessons from extended induction and practical evidence for improving tofacitinib therapy in ulcerative colitis.

World journal of gastroenterology·2026
Same journal

Small animal <i>ex vivo</i> machine perfusion of the liver: A comprehensive literature review.

World journal of gastroenterology·2026
Same journal

Comparable remission and health care use in real-world inflammatory bowel disease patients initiating originator biologics <i>vs</i> biosimilars.

World journal of gastroenterology·2026
Same journal

Diagnosis and management of metabolic dysfunction-associated steatohepatitis in patients with chronic hepatitis B infection.

World journal of gastroenterology·2026
Same journal

Simultaneous treatment of concomitant achalasia coexisting with epiphrenic diverticulum: The practice of submucosal tunneling technique.

World journal of gastroenterology·2026
Same journal

Lianhe Xiaozhi ointment ameliorates metabolic dysfunction-associated steatotic liver disease <i>via</i> peroxisome proliferator-activated receptor alpha pathway activation.

World journal of gastroenterology·2026
See all related articles

Related Experiment Video

Updated: Apr 7, 2026

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.4K

Gene polymorphisms associated with functional dyspepsia.

Anastasia Kourikou1, George P Karamanolis1, George D Dimitriadis1

  • 1Anastasia Kourikou, George D Dimitriadis, Konstantinos Triantafyllou, Hepatogastroenterology Unit, Second Department of Internal Medicine and Research Institute, Attikon University General Hospital, Medical School, Athens University, 12462 Haidari, Greece.

World Journal of Gastroenterology
|July 14, 2015
PubMed
Summary
This summary is machine-generated.

Genetic factors likely influence functional dyspepsia (FD) susceptibility, but current research on gene polymorphisms shows contradictory results. Further studies are needed to clarify the role of specific genes in FD.

Keywords:
Functional dyspepsiaGene polymorphismGenetic susceptibilityPathophysiology

More Related Videos

An Allele-specific Gene Expression Assay to Test the Functional Basis of Genetic Associations
10:17

An Allele-specific Gene Expression Assay to Test the Functional Basis of Genetic Associations

Published on: November 3, 2010

23.4K
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

10.6K

Related Experiment Videos

Last Updated: Apr 7, 2026

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.4K
An Allele-specific Gene Expression Assay to Test the Functional Basis of Genetic Associations
10:17

An Allele-specific Gene Expression Assay to Test the Functional Basis of Genetic Associations

Published on: November 3, 2010

23.4K
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

10.6K

Area of Science:

  • Gastroenterology
  • Genetics
  • Internal Medicine

Background:

  • Functional dyspepsia (FD) presents with upper abdominal complaints, and its pathophysiology remains unclear.
  • Growing evidence suggests a hereditary component influencing susceptibility to FD.
  • Previous genetic studies have explored various gene polymorphisms related to gastrointestinal function and immune responses.

Purpose of the Study:

  • To review genetic association studies investigating gene polymorphisms in relation to functional dyspepsia.
  • To highlight the inconsistencies and limitations in current research.
  • To emphasize the need for well-designed future studies.

Main Methods:

  • Review of existing genetic association studies on functional dyspepsia.
  • Identification of investigated gene polymorphisms, including G-protein b3 subunit, serotonin transporter, and others.
  • Analysis of reported associations and contradictions in study findings.

Main Results:

  • Numerous gene polymorphisms have been investigated for association with FD, with often contradictory results.
  • Genes examined include those involved in motility, sensation, inflammation, and immune response.
  • Limitations such as inconsistent definitions, subject heterogeneity, and environmental factors affect study validity.

Conclusions:

  • The precise role of gene polymorphisms in functional dyspepsia pathophysiology is not yet established.
  • Contradictory findings necessitate further rigorous research.
  • Future studies should address current limitations to elucidate the genetic basis of FD and guide therapeutic strategies.